The Commercial End for Fluidigm Technology?

Last week brought news that Standard Biotools, which is what Fluidigm morphed into, is being acquired by Treeline Biosciences, a drug developer.  The deal values Standard at about its cash position - and Treeline made it immediately clear this is a reverse merger to grab the cash and in effect go public by also grabbing Standard's stock listing.  What Treeline has made very clear is that they have absolutely no interest in is Standard's existing tools portfolio.

This is not an uncommon playbook - companies often acquire other companies for very specific assets and see everything else as excess baggage.  Long before my two year stint at Infinity Pharmaceuticals, they had gone public by buying up a public company with a stock listing.  Revolution Medicines wanted Warp Drive Bio just for the chemistry that led to daraxonrasib, which has moved the needle on pancreatic cancer survival for the first time in decades, and had no interest in our genome mining platform.  The end result of all that was a brief resume entry for me with RevMed and our group being sold to Ginkgo (and in the full disclosure department, yes I still hold RevMed stock).  After the turn-of-the-century internet bubble broke, some really strange reverse mergers happened - notoriously (though I can't find it now on the nets) an online purveyor of funeral services merged with a biotech.

Standard Biotools was a rebranding of Fluidigm, displaying an ambition to become a shop with a diversified portfolio of molecular tools.  The logo harkened back to Standard Oil, a colossus which had been broken up into "The Seven Sisters" which, even after a few mergers, are still amongst the biggest players of the oil industry.  If you have read Daniel Yergin's The Prize, you know that story - if you haven't get thee to the bookshelf!  Though to be realistic, how many modern biologists even recognized the allusion, since Amoco (nee Standard Oil of Indiana) had given up the similar logo many years ago.

Fluidigm had started with microfluidics technology based on the polymer PVDMS.  This polymer has a number of interesting properties, starting with high flexibility - Fluidigm's "fluidic circuits" worked by using air pressure in lines through one layer of the device to compress closed fluid lines in another layer.  The company's controller instrument would work all this on consumables that were built around a particular application.

As I understand it, Fluidigm saw some success early on with using their circuits for exploring crystallization conditions for protein crystallography.  I was most familiar with their scheme that basically allowed crossing a number of PCR reactions vs. a number of samples - basically X-axis lines had reactions, Y-axis samples (or vice-versa) and at each intersection a PCR reaction could be formed.  Clever early approach to avoid multiplex PCR for targeted NGS, but these days we are awash in clever multiplex PCR schemes that don't have the fixed number of reactions and chips of the Fluidigm chips.  Plus you need no specialized equipment - just liquid handlers and ordinary thermocyclers.

As an aside, when I was at Infinity I tried to do a collaboration with Fluidigm, driven in part by my friend Chris S. being in their sales group.  But, to be honest, I was always hoping Fluidigm would pay for my amazing idea to show off their technology and they were always hoping I'd be a paying customer, so we never quite got very far.

Fluidigm launched a product for single cell RNA-Seq - but again, got passed by market leaders such as 10X Genomics.  Fluidigm's approach could sequence only small numbers of cells, and as sequencing got cheap everybody wanted large numbers.

Along the way, Fluidigm bought a company with a cool technology called CyTOF, which uses metal-labeled antibodies to analyze levels of up to about 50 proteins in individual cells.  Cells are labeled with antibodies, nebulized and then shot into a time-of-flight mass spectrometer to be vaporized and analyzed - if the cells are at sufficiently low frequency in the stream then there will be bursts of signal separated by periods of no signal - each burst is the data for one cell.  Cool single cell proteomics, but it would appear from Standard's revenue figures it isn't setting the world on fire.  There's also a cellular imaging system in the portfolio.

Standard's big score was to acquire SomaLogic and their proteomics-by-sequencing approach using aptamers.  Flipping SomaLogic over to Illumina would appear to be responsible for most of the cash that Treeline is now grabbing - $350M sale and Standard currently has $370M.

Treeline has declared they want no part of the tools business, but Standard's management is apparently being given some leash to try to find buyers.  Sounds familiar - the day Warp's acquisition by RevMed was announced we were told nobody knew what would happen to genome mining - we were hardly a footnote to the transaction.  But everyone started throwing out ideas of who might want to buy us, and while that list attritted quickly (two candidates extinguished their R&D operations during that period) Ginkgo became a good home.

Standard's Q1 revenue was $21.1M, just over half of that consumables.  Full year revenue for 2026 was apparently (according to Gemini) to be about on par with 2025 revenue - in other words, flat.  Management had put a happy face on this, claiming that "adjusted EBITDA" would be break even this year.  The only problem with that is "adjusted EBITDA" is a very squishy formula, something akin to von Neumann's 6 degrees-of-freedom elephant.   Could a buyer be found for these assets?  Either some true believer willing to gamble that with a new, lean corporate structure they could slowly grow the business or a big conglomerate such as ThermoFisher or Agilent that could service customers mostly off their existing sales, marketing, and support infrastructure.

But CyToF, the Hyperion imaging system, and BioMark (the microfluidics products) might just be doomed.  They're small product lines that are technologically complex.  Possible buyers may have their acquisition eyes elsewhere.  And that is a perpetual danger for those of us who rely on specialized tools that have failed to achieve broad product-market fit.  I have a number of AGBT giveaways still - such as a favored CLiC shotglass - that are fossils of interesting products that have since been discontinued. And the fear of that fate can be a significant headwind on adoption of a niche technology - what if the company folds?  And if that happens then it becomes a doom loop - nobody using a tech because everybody is afraid not enough people will use it.  

I've seen some interesting applications of the BioMark controller for genomics, particularly from Paul Blainey's group at The Broad Institute.  A particularly unhappy outcome would be BioMark going off the market but the IP rights around it being held murkily, preventing anyone from building in this space.  Of course, it may be that many of the key PVDMS microfluidics patents may be aging out and that won't be an issue.